(Q37982927)

26 August 2017

title

Cancer biomarkers: selecting the right drug for the right patient (English)

1 reference

26 August 2017

0 references

1 reference

Gary J Kelloff

1

1 reference

26 August 2017

Caroline C Sigman

series ordinal

2

1 reference

26 August 2017

language of work or name

1 reference

10 February 2012

1 reference

Nature Reviews Drug Discovery

26 August 2017

published in

1 reference

26 August 2017

volume

11

1 reference

26 August 2017

issue

3

1 reference

26 August 2017

page(s)

201-214

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd3651

26 August 2017

exact match

0 references

cites work

The Hallmarks of Cancer

1 reference

Hallmarks of Cancer: The Next Generation

31 March 2020

1 reference

Principles of cancer therapy: oncogene and non-oncogene addiction

31 March 2020

1 reference

Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits

31 March 2020

1 reference

How to improve R&D productivity: the pharmaceutical industry's grand challenge

31 March 2020

1 reference

Breast tumor heterogeneity: causes and consequences

31 March 2020

1 reference

The role of the microenvironment in mammary gland development and cancer

31 March 2020

1 reference

HER-2/neu as a predictive marker of response to breast cancer therapy

31 March 2020

1 reference

Perspectives on the development of imatinib and the future of cancer research

31 March 2020

1 reference

Targeting BRAF in advanced melanoma: a first step toward manageable disease

31 March 2020

1 reference

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

31 March 2020

1 reference

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

31 March 2020

1 reference

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

31 March 2020

1 reference

Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)

31 March 2020

1 reference

Epidermal growth factor receptor inhibitors in non-small cell lung cancer

31 March 2020

1 reference

Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development

31 March 2020

1 reference

The US Food and Drug Administration perspective on cancer biomarker development.

31 March 2020

1 reference

Integration and use of biomarkers in drug development, regulation and clinical practice: a US regulatory perspective

31 March 2020

1 reference

Taming the dragon: genomic biomarkers to individualize the treatment of cancer.

31 March 2020

1 reference

Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents.

31 March 2020

1 reference

Cancer as an evolutionary and ecological process

31 March 2020

1 reference

Candidate-based proteomics in the search for biomarkers of cardiovascular disease

31 March 2020

1 reference

Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward

31 March 2020

1 reference

Emerging molecular markers of cancer.

31 March 2020

1 reference

Genetic alterations during colorectal-tumor development

31 March 2020

1 reference

Genetic pathways in colorectal and other cancers

31 March 2020

1 reference

A genetic model for colorectal tumorigenesis

31 March 2020

1 reference

The molecular biology of breast cancer: accelerating clinical applications

31 March 2020

1 reference

PTEN function: how normal cells control it and tumour cells lose it

31 March 2020

1 reference

Human cancer, PTEN and the PI-3 kinase pathway

31 March 2020

1 reference

The biology and clinical relevance of the PTEN tumor suppressor pathway

31 March 2020

1 reference

Reanalysis of cancer drugs: old drugs, new tricks

31 March 2020

1 reference

Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus

31 March 2020

1 reference

Biomarkers in Barrett's esophagus

31 March 2020

1 reference

Targeting the missing links for cancer therapy

31 March 2020

1 reference

Molecular markers for the diagnosis and management of ductal carcinoma in situ

31 March 2020

1 reference

Molecular subtypes in breast cancer evaluation and management: divide and conquer

31 March 2020

1 reference

A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer

31 March 2020

1 reference

Stromal gene signatures in large-B-cell lymphomas

31 March 2020

1 reference

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

31 March 2020

1 reference

Accumulation of driver and passenger mutations during tumor progression

31 March 2020

1 reference

An integrated genomic analysis of human glioblastoma multiforme

31 March 2020

1 reference

Mutational heterogeneity in human cancers: origin and consequences.

31 March 2020

1 reference

Noninvasive evaluation of oral lesions using depth-sensitive optical spectroscopy

31 March 2020

1 reference

Optical imaging for cervical cancer detection: solutions for a continuing global problem

31 March 2020

1 reference

Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development

31 March 2020

1 reference

Understanding the Warburg effect: the metabolic requirements of cell proliferation

31 March 2020

1 reference

Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use.

31 March 2020

1 reference

Is 18F-FDG PET/CT useful for the early prediction of histopathologic response to neoadjuvant erlotinib in patients with non-small cell lung cancer?

31 March 2020

1 reference

Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography.

31 March 2020

1 reference

Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib

31 March 2020

1 reference

Molecular predictors of response to therapy for breast cancer

31 March 2020

1 reference

Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20.

31 March 2020

1 reference

Converting a breast cancer microarray signature into a high-throughput diagnostic test.

31 March 2020

1 reference

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

31 March 2020

1 reference

I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy

31 March 2020

1 reference

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

31 March 2020

1 reference

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

31 March 2020

1 reference

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

31 March 2020

1 reference

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

31 March 2020

1 reference

Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer.

31 March 2020

1 reference

Biological Markers in Epidemiologic Research

31 March 2020

1 reference

Clinical biomarkers in drug discovery and development

31 March 2020

1 reference

Human Cancer Syndromes: Clues to the Origin and Nature of Cancer

31 March 2020

1 reference

Pharmacogenomic-guided drug development: regulatory perspective

31 March 2020

1 reference

New science-based endpoints to accelerate oncology drug development

31 March 2020

1 reference

Comparing breast cancer risk assessment models

31 March 2020

1 reference

Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application

31 March 2020

1 reference

Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development

31 March 2020

1 reference

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

31 March 2020

1 reference

Circulating tumor cells as biomarkers in prostate cancer

31 March 2020

1 reference

Circulating tumor cells in breast cancer: a tool whose time has come of age

31 March 2020

1 reference

Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs

31 March 2020

1 reference

Accelerated approval of oncology products: the food and drug administration experience

31 March 2020

1 reference

Circulating tumors cells as biomarkers: progress toward biomarker qualification

31 March 2020

1 reference

Comparison of treatment response classifications between unidimensional, bidimensional, and volumetric measurements of metastatic lung lesions on chest computed tomography1

31 March 2020

1 reference

Imaging surrogates of tumor response to therapy: anatomic and functional biomarkers

31 March 2020

1 reference

Integrating predictive biomarkers and classifiers into oncology clinical development programmes

31 March 2020

1 reference

On the efficiency of targeted clinical trials

31 March 2020

1 reference

Randomized clinical trials with biomarkers: design issues

31 March 2020

1 reference

The cross-validated adaptive signature design

31 March 2020

1 reference

31 March 2020

Bayesian clinical trials

1 reference

Validation of pharmacogenomic biomarker classifiers for treatment selection.

31 March 2020

1 reference

Development and evaluation of therapeutically relevant predictive classifiers using gene expression profiling

31 March 2020

1 reference

Development and Validation of Biomarker Classifiers for Treatment Selection

31 March 2020

1 reference

Randomized phase III clinical trial designs for targeted agents

31 March 2020

1 reference

The future of drug development: advancing clinical trial design.

31 March 2020

1 reference

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

31 March 2020

1 reference

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

31 March 2020

1 reference

Enrichment designs: efficiency in development of cancer treatments

31 March 2020

1 reference

The BATTLE trial: a bold step toward improving the efficiency of biomarker-based drug development

31 March 2020

1 reference

The BATTLE to personalize lung cancer prevention through reverse migration

31 March 2020

1 reference

The BATTLE trial: personalizing therapy for lung cancer

31 March 2020

1 reference

Adaptive clinical trials in oncology

31 March 2020

1 reference

Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients

31 March 2020

1 reference

Biomarker-adaptive clinical trial designs

31 March 2020

1 reference

Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study

31 March 2020

1 reference

The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee

31 March 2020

1 reference

Optimising the design of phase II oncology trials: the importance of randomisation.

31 March 2020

1 reference

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

31 March 2020

1 reference

Integrated genomic analyses of ovarian carcinoma

31 March 2020

1 reference

Cancer genomics: from discovery science to personalized medicine

31 March 2020

1 reference

A policy approach to the development of molecular diagnostic tests

31 March 2020

1 reference

Fit-for-purpose method development and validation for successful biomarker measurement.

31 March 2020

1 reference

The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group

31 March 2020

1 reference

Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design

31 March 2020

1 reference

The natural history of intraepithelial neoplasia: relevance to the search for intermediate endpoint biomarkers

31 March 2020

1 reference

12 December 2020

Intraepithelial and postinvasive neoplasia as a stochastic continuum of clonal evolution, and its relationship to mechanisms of chemopreventive drug action

1 reference

12 December 2020

Epigenetics in cancer: what's the future?

1 reference

12 December 2020

Natural history of intraepithelial neoplasia in humans with implications for cancer chemoprevention strategy

1 reference

12 December 2020

Therapeutic exploitation of the physiological and molecular genetic alterations in head and neck cancer.

1 reference

12 December 2020

Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD3651

1 reference

26 August 2017

1 reference